Related Experiment Video

Updated: Aug 8, 2026

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Effects of recombinant leukocyte interferon on serum immunoglobulin concentrations and lymphocyte subpopulations in

H Tsuji1, K Murai, K Akagi

  • 1Second Department of Internal Medicine, Faculty of Medicine, Kyushu University, Fukuoka, Japan.

Journal of Clinical Immunology
|January 1, 1990
PubMed

Insights

Interferon (IFN) therapy for chronic hepatitis B significantly reduced immunoglobulin levels in patients. These immune changes, including decreased immunoglobulin A, G, and M, returned to normal levels post-treatment.

Area of Science:

  • Immunology
  • Hepatology
  • Virology

Background:

  • Chronic hepatitis B infection is a significant global health concern.
  • Hepatitis B e antigen (HBeAg)-positive status indicates active viral replication.
  • Interferon (IFN) therapy is used to manage chronic hepatitis B.

Purpose of the Study:

  • To investigate the immune effects of interferon (IFN) therapy in HBeAg-positive chronic hepatitis B patients.
  • To assess changes in serum immunoglobulin concentrations during and after IFN treatment.

Main Methods:

  • Nine patients with HBeAg-positive chronic hepatitis B received recombinant human alpha-IFN therapy.
  • Serum immunoglobulin levels (IgA, IgG, IgM) were measured before, during (weekly), and after therapy.
  • Peripheral lymphocyte subpopulations were also studied sequentially.

Main Results:

  • Significant reductions in serum immunoglobulin A, G, and M levels were observed during IFN therapy.
  • Immunoglobulin A decreased from baseline to a bottom value of 323 +/- 20 mg/dl (P < 0.001).
  • Immunoglobulin G decreased from baseline to a bottom value of 2005 +/- 199 mg/dl (P < 0.001).
  • Immunoglobulin M levels were significantly reduced after 3 weeks of therapy (P < 0.01).

Conclusions:

  • Recombinant human alpha-IFN therapy impacts immunoglobulin levels in chronic hepatitis B patients.
  • The observed reductions in IgA, IgG, and IgM returned to pretreatment levels by 4 months post-therapy.
  • Further research is needed to understand the clinical implications of these immune modulations.

More Related Videos

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...